Table 6.

Enriched X. laevis pathways due to cyclopamine treatment using SEPEA_NT2*

KEGG pathway ID	Pathway description	P-value
[path:xla00930]	Caprolactam degradation	0.006
[path:xla03030]	DNA replication	0.011
[path:xla00480]	Glutathione metabolism	0.016
[path:xla00561]	Glycerolipid metabolism	0.023
[path:xla03010]	Ribosome	0.045
[path:xla00982]	Drug metabolism - cytochrome P450	0.057
[path:xla00983]	Drug metabolism - other enzymes	0.057
[path:xla04012]	ErbB signaling	0.067
[path:xla03060]	Protein export	0.072
[path:xla00562]	Inositol phosphate metabolism	0.086
[path:xla04914]	Progesterone-mediated oocyte maturation	0.087
[path:xla04020]	Calcium signaling pathway	0.089

Enriched KEGG [44] pathways (with P-value ≤ 0.1) due to cyclopamine treatment of developing X. laevis, designed to inhibit SHH signaling, using microarray data from GEO [45] [GEO:GSE8293]. P-values were obtained using the SEPEA_NT2* analysis with 1,000 randomizations to compute significance.